© Drug Hunter Inc. 2018-2023
Home > GNF2133
GSK3β-sparing DYRK1A kinase inhibitor
orally efficacious in proliferation model, but non-specific proliferation observed
from cellular phenotypic screen and opt.
J. Med. Chem. Feb. 20, 2020
Novartis (GNF), San Diego, CA
GNF2133 (Novartis (GNF) oral in vivo GSK3-beta-sparing DYRK1A kinase inhibitor)
You don’t have time to read everything, but you can’t afford to fall behind.
Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.
Get ahead now by requesting a trial.
Molecules of the Month
Molecule of the Year